Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
National Heart Research Institute Singapore, National Heart Centre, Singapore, Singapore.
Sci Rep. 2018 Jun 26;8(1):9713. doi: 10.1038/s41598-018-27950-9.
To investigate whether metformin add-on to the continuous subcutaneous insulin infusion (Met + CSII) therapy leads to a significant reduction in insulin doses required by type 2 diabetes (T2D) patients to maintain glycemic control, and an improvement in glycemic variation (GV) compared to CSII only therapy. We analyzed data from our two randomized, controlled open-label trials. Newly diagnoses T2D patients were randomized assigned to receive either CSII therapy or Met + CSII therapy for 4 weeks. Subjects were subjected to a 4-day continuous glucose monitoring (CGM) at the endpoint. Insulin doses and GV profiles were analyzed. The primary endpoint was differences in insulin doses and GV between the two groups. A total of 188 subjects were admitted as inpatients. Subjects in metformin add-on therapy required significantly lower total, basal and bolus insulin doses than those of control group. CGM data showed that patients in Met + CSII group exhibited significant reduction in the 24-hr mean amplitude of glycemic excursions (MAGE), the standard deviation, and the coefficient of variation compared to those of control group. Our data suggest that metformin add-on to CSII therapy leads to a significant reduction in insulin doses required by T2D patients to control glycemic variations.
为了研究二甲双胍联合持续皮下胰岛素输注（Met+CSII）治疗是否会显著减少 2 型糖尿病（T2D）患者控制血糖所需的胰岛素剂量，并改善血糖变异性（GV），与单独 CSII 治疗相比。我们分析了来自我们两项随机、对照、开放标签试验的数据。新诊断的 T2D 患者被随机分配接受 CSII 治疗或 Met+CSII 治疗 4 周。在终点时，受试者接受了 4 天的连续血糖监测（CGM）。分析了胰岛素剂量和 GV 曲线。主要终点是两组之间胰岛素剂量和 GV 的差异。共有 188 名受试者作为住院患者入院。与对照组相比，接受二甲双胍联合治疗的受试者所需的总、基础和餐时胰岛素剂量显著降低。CGM 数据显示，与对照组相比，Met+CSII 组患者 24 小时平均血糖波动幅度（MAGE）、标准差和变异系数显著降低。我们的数据表明，二甲双胍联合 CSII 治疗可显著减少 T2D 患者控制血糖变异性所需的胰岛素剂量。
